42 related articles for article (PubMed ID: 21646468)
1. Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation.
Oussenko IA; Holland JF; Reddy EP; Ohnuma T
Cancer Res; 2011 Jul; 71(14):4968-76. PubMed ID: 21646468
[TBL] [Abstract][Full Text] [Related]
2. A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.
Athuluri-Divakar SK; Vasquez-Del Carpio R; Dutta K; Baker SJ; Cosenza SC; Basu I; Gupta YK; Reddy MV; Ueno L; Hart JR; Vogt PK; Mulholland D; Guha C; Aggarwal AK; Reddy EP
Cell; 2016 Apr; 165(3):643-55. PubMed ID: 27104980
[TBL] [Abstract][Full Text] [Related]
3. Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma.
Chang KC; Chang WC; Chang Y; Hung LY; Lai CH; Yeh YM; Chou YW; Chen CH
PLoS One; 2013; 8(11):e79863. PubMed ID: 24223200
[TBL] [Abstract][Full Text] [Related]
4. Determinants of small ubiquitin-like modifier 1 (SUMO1) protein specificity, E3 ligase, and SUMO-RanGAP1 binding activities of nucleoporin RanBP2.
Gareau JR; Reverter D; Lima CD
J Biol Chem; 2012 Feb; 287(7):4740-51. PubMed ID: 22194619
[TBL] [Abstract][Full Text] [Related]
5. RanBP1 governs spindle assembly by defining mitotic Ran-GTP production.
Zhang MS; Arnaoutov A; Dasso M
Dev Cell; 2014 Nov; 31(4):393-404. PubMed ID: 25458009
[TBL] [Abstract][Full Text] [Related]
6. The RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase.
Werner A; Flotho A; Melchior F
Mol Cell; 2012 May; 46(3):287-98. PubMed ID: 22464730
[TBL] [Abstract][Full Text] [Related]
7. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
Chapman CM; Sun X; Roschewski M; Aue G; Farooqui M; Stennett L; Gibellini F; Arthur D; Pérez-Galán P; Wiestner A
Clin Cancer Res; 2012 Apr; 18(7):1979-91. PubMed ID: 22351695
[TBL] [Abstract][Full Text] [Related]
8. Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na).
Monfort-Vengut A; de Cárcer G
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111716
[TBL] [Abstract][Full Text] [Related]
9. Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition.
Islam S; Rahaman MH; Yu M; Noll B; Martin JH; Wang S; Head R
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831387
[TBL] [Abstract][Full Text] [Related]
10. Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent.
Malacrida A; Deschamps-Wright M; Rigolio R; Cavaletti G; Miloso M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675237
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.
Malacrida A; Rigolio R; Celio L; Damian S; Cavaletti G; Mazzaferro V; Miloso M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360994
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of
Zhou X; Xiao Q; Fu D; Zhang H; Tang Y; He J; Hu Y; Kong X; Teng F; Liu X; Yuan Y; Ding K
Cancer Biol Med; 2021 Aug; 19(2):213-28. PubMed ID: 34347396
[TBL] [Abstract][Full Text] [Related]
13. Microtubule Depolymerization by Kinase Inhibitors: Unexpected Findings of Dual Inhibitors.
Tanabe K
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29168788
[TBL] [Abstract][Full Text] [Related]
14. Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent.
Jost M; Chen Y; Gilbert LA; Horlbeck MA; Krenning L; Menchon G; Rai A; Cho MY; Stern JJ; Prota AE; Kampmann M; Akhmanova A; Steinmetz MO; Tanenbaum ME; Weissman JS
Mol Cell; 2017 Oct; 68(1):210-223.e6. PubMed ID: 28985505
[TBL] [Abstract][Full Text] [Related]
15. Changes in Transcript Related to Osmosis and Intracellular Ion Homeostasis in Paulownia tomentosa under Salt Stress.
Fan G; Wang L; Deng M; Zhao Z; Dong Y; Zhang X; Li Y
Front Plant Sci; 2016; 7():384. PubMed ID: 27066034
[TBL] [Abstract][Full Text] [Related]
16. The novel tubulin polymerization inhibitor MHPT exhibits selective anti-tumor activity against rhabdomyosarcoma in vitro and in vivo.
Mu Y; Liu Y; Li L; Tian C; Zhou H; Zhang Q; Yan B
PLoS One; 2015; 10(3):e0121806. PubMed ID: 25811876
[TBL] [Abstract][Full Text] [Related]
17. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells.
Wang NN; Li ZH; Zhao H; Tao YF; Xu LX; Lu J; Cao L; Du XJ; Sun LC; Zhao WL; Xiao PF; Fang F; Su GH; Li YH; Li G; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Ni J; Wang J; Hu SY; Zhu XM; Feng X; Pan J
Int J Mol Sci; 2015 Jan; 16(1):1266-92. PubMed ID: 25574601
[TBL] [Abstract][Full Text] [Related]
19. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
